Solventum (NYSE:SOLV) Price Target Raised to $84.00 at Piper Sandler

Solventum (NYSE:SOLV) had its target price boosted by investment analysts at Piper Sandler from $75.00 to $84.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective points to a potential upside of 0.65% from the stock’s current price.

SOLV has been the topic of several other research reports. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. Finally, Morgan Stanley raised their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and a consensus target price of $73.14.

Solventum Stock Performance

SOLV stock opened at $83.46 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company’s 50-day moving average is $72.25 and its 200-day moving average is $69.73. Solventum has a 1 year low of $47.16 and a 1 year high of $96.05.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently made changes to their positions in SOLV. Vanguard Group Inc. boosted its holdings in Solventum by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company’s stock worth $1,074,591,000 after purchasing an additional 75,631 shares during the last quarter. Trian Fund Management L.P. lifted its position in shares of Solventum by 18.8% during the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company’s stock worth $559,054,000 after buying an additional 1,336,564 shares in the last quarter. State Street Corp boosted its stake in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after buying an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Solventum by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company’s stock valued at $227,992,000 after acquiring an additional 112,686 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Solventum during the fourth quarter valued at approximately $203,740,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.